News
- Author:
- Mary Ellen Schneider
Publish date: February 29, 2020
Health officials in Washington state said they are investigating a long-term care facility with two presumptive positive cases of COVID-19 and more...
Video
- Author:
- Mary Ellen Schneider
Publish date: January 22, 2020
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of th...
News
- Author:
- Mary Ellen Schneider
Publish date: January 2, 2020
Dr. Osunkwo is a specialist in sickle cell disease and the director of the sickle cell program at Levine Cancer Institute in Charlotte, N.C.
News
- Author:
- Mary Ellen Schneider
Publish date: December 10, 2019
ORLANDO – The list, which was released by ASH and the American Society of Pediatric Hematology/Oncology, includes five unnecessary tests or procedu...
News
- Author:
- Mary Ellen Schneider
Publish date: December 7, 2019
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
News
- Author:
- Mary Ellen Schneider
Publish date: November 15, 2019
Crizanlizumab-tmca (Adakveo) is approved for patients with sickle cell disease who are aged 16 years and older.
News
- Author:
- Mary Ellen Schneider
Publish date: November 8, 2019
Luspatercept-aamt (Reblozyl) is approved for adults with beta thalassemia who require regular red blood cell transfusions.
News
- Author:
- Mary Ellen Schneider
Publish date: October 23, 2019
The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.
News
- Author:
- Mary Ellen Schneider
Publish date: October 23, 2019
The observational trial showed that survival was significantly higher with transplant than with chemotherapy consolidation therapy in patients with...
News
- Author:
- Mary Ellen Schneider
Publish date: October 18, 2019
The drug is now indicated for newly diagnosed and persistent adult patients with immune thrombocytopenia and an insufficient response to other trea...
News
- Author:
- Mary Ellen Schneider
Publish date: October 11, 2019
Genentech says the benefit-risk profile of the hemophilia A product is unchanged, and it will continue to be distributed.
News
- Author:
- Mary Ellen Schneider
Publish date: September 6, 2019
The study did not find a survival advantage for patients who had salvage therapy to deepen their responses before moving on to transplant.
News
- Author:
- Mary Ellen Schneider
Publish date: August 27, 2019
The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one prior...
News
- Author:
- Mary Ellen Schneider
Publish date: August 7, 2019
The treatment approach can be used safely with concurrent chemotherapy.
News
- Author:
- Mary Ellen Schneider
Publish date: July 23, 2019
The new pathway allows oncologists to choose a focused exam in hematologic malignancies, breast cancer, or general oncology every 2 years, starting...
